Mar 21, 2024 7:00 am EDT Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 13, 2024 4:05 pm EDT Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
Jan 29, 2024 4:05 pm EST Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
Dec 21, 2023 4:05 pm EST Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Nov 11, 2023 11:30 am EST Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
Nov 07, 2023 4:05 pm EST Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 02, 2023 10:00 am EDT Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
